Hi-Tech Pharma Announces ECR Pharma Re-Launched Zolpimist, DexPak, Divestiture of Hylase, Orbivan Brands

Hi-Tech Pharmacal Co., Inc.

today announced that its ECR Pharmaceuticals division re-launched Zolpimist® Oral Spray (zolpidem tartrate) and DexPak® Taperpaks (dexamethasone tablets) through its proprietary sales force at a series of launch meetings commencing this week. Additionally, ECR has divested its interest in non-core products Hylase® and Orbivan®. Hylase was divested for a one-time payment in January, and Orbivan® was divested in March for $500,000 over two payments and an ongoing royalty stream.